PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14965331-12	2004	Therefore, it is suggested that the activation of dopamine synthesis and the moderate level of MAOB inhibition are main mechanisms of ZNS effects on PD.	Zonisamide	134-137	monoamine oxidase B	Homo sapiens	95-99	
30160213-6	2019	Safinamide is the prototype of a new generation of multi-active MAOB inhibitors, which includes the antiepileptic drug, zonisamide.	Zonisamide	120-130	monoamine oxidase B	Homo sapiens	64-68	
25261037-1	2015	Zonisamide has been reported to have protective effects on epilepsy and Parkinson s disease and to work via various mechanisms of action, such as inhibition of monoamine oxidase-B and enhancement of tyrosine hydroxylase.	Zonisamide	0-10	monoamine oxidase B	Homo sapiens	160-179	
21175212-0	2011	Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex.	Zonisamide	63-73	monoamine oxidase B	Homo sapiens	128-147	
19948168-5	2010	We also discovered that zonisamide inhibited monoamine oxidase B (MAO-B) activity in vitro with an IC(50) of 25 muM, a concentration that is well within the therapeutic range used for treating epilepsy in humans.	Zonisamide	24-34	monoamine oxidase B	Homo sapiens	45-64	
19948168-5	2010	We also discovered that zonisamide inhibited monoamine oxidase B (MAO-B) activity in vitro with an IC(50) of 25 muM, a concentration that is well within the therapeutic range used for treating epilepsy in humans.	Zonisamide	24-34	monoamine oxidase B	Homo sapiens	66-71	
19948168-9	2010	The potency and reversibility with which zonisamide blocks MAO-B may contribute to the ability of the drug to improve clinical symptoms in PD patients.	Zonisamide	41-51	monoamine oxidase B	Homo sapiens	59-64